Clonitazene

Summary

Clonitazene is an opioid pain reliever that boasts nearly triple the potency of morphine. This compound shares a kinship with etonitazene, an opioid with notably greater power. Clonitazene is not commercially available at present. Regarded as a controlled substance, it holds a Schedule I classification in the United States as a Narcotic controlled substance, identified by the DEA with the code ACSCN 9612. For the year 2022, an established manufacturing allowance of 25 grams has been set.

Identifiers
IUPAC name
CAS Number3861-76-5 
PubChem CID62528
DrugBankDB01523 
ChemSpider56301 
UNIIS90R21A2V2
KEGGD12668 
ChEMBLChEMBL2104616 
CompTox Dashboard (EPA)DTXSID90191931
Chemical and physical data
FormulaC20H23ClN4O2
Molar mass386.88 g·mol−1

FAQ

  • What is Clonitazene?
  • Clonitazene is an opioid analgesic, a type of pain-relieving medication. It is known for its high potency, approximately three times that of morphine.
  • How is Clonitazene used?
  • Clonitazene is typically used to relieve severe pain, such as that resulting from surgery or certain medical conditions. It is administered under medical supervision and is not intended for self-administration.
  • Is Clonitazene available for purchase or prescribed?
  • Clonitazene is not currently marketed or prescribed for medical use. It is considered a controlled substance and is not available through traditional medical channels.
  • What is the potency of Clonitazene compared to morphine?
  • Clonitazene is approximately three times more potent than morphine. This heightened potency makes it a powerful pain-relief option.
  • Is Clonitazene legal?
  • Clonitazene is classified as a controlled substance in many regions, including the United States, where it is designated as a Schedule I Narcotic controlled substance. This means it is illegal to manufacture, possess, or distribute.
  • What is the DEA ACSCN for Clonitazene?
  • The Drug Enforcement Administration (DEA) assigns Clonitazene the ACSCN (Alpha-numeric Code for Controlled Substances) of 9612.
  • Is there a manufacturing quota for Clonitazene?
  • Yes, there is an established manufacturing quota for Clonitazene, with a limit of 25 grams for the year 2022. This quota regulates the production and distribution of the substance.
  • Are there risks associated with Clonitazene use?
  • Yes, using Clonitazene carries significant risks, including the potential for addiction, overdose, and severe side effects. It should only be used under strict medical supervision when deemed necessary.
  • What should I do if I encounter Clonitazene or suspect its use?
  • If you encounter Clonitazene or suspect its use, it is essential to report it to the appropriate authorities. Unauthorized possession or distribution of controlled substances is illegal and can have serious legal consequences.
  • Where can I get help for opioid-related issues?
    If you or someone you know is struggling with opioid-related issues or addiction, it is crucial to seek professional help immediately. You can contact addiction treatment centers, healthcare providers, or addiction helplines for guidance and support. Opioid addiction is a serious health concern that should be addressed promptly.

References

  1. Anvisa (2023-03-31): “Resolution of the Collegiate Board No. 784 – Catalogs of Controlled Narcotic, Psychotropic, Precursor, and Other Special Substances” [Original title: “RDC Nº 784 – Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial”] (in Brazilian Portuguese). Published in the Diário Oficial da União on 2023-04-04. Archived from the original on 2023-08-03. Retrieved on 2023-08-16.
  2. Hunger A, Kebrle J, Rossi A, Hoffmann K (October 1957): “Synthesis of Benzimidazole Derivatives with Alkaline Substitutions for Analgesic Purposes” [Original title: “Synthesis of analgesically active benzimidazole derivatives with basic substitutions”]. Published in Experientia. Volume 13, Issue 10, pages 400–1. doi: 10.1007/BF02161116. PMID: 13473817. S2CID: 32179439.

Leave a Comment

Your email address will not be published. Required fields are marked *